Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX3 | P56373 | 5/20 | 0.49 |
| ▸ | P2RX1 | P51575 | 4/20 | 0.49 |
| ▸ | P2RX2 | Q9UBL9 | 3/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | P2RX4 | Q99571 | 4/20 | 0.48 |
| ▸ | P2RY1 | P47900 | 3/20 | 0.47 |
| ▸ | P2RY2 | P41231 | 2/20 | 0.47 |
| ▸ | SRC | P12931 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | RNASEL | Q05823 | 1/20 | 0.46 |
| ▸ | DTYMK | P23919 | 2/20 | 0.46 |
| ▸ | CHAT | P28329 | 1/20 | 0.46 |
| ▸ | AURKA | O14965 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24913298 | 1.00 | P2RX3 (0.49) | P2RX3P2RX1P2RX2POLBP2RX4 | |
| SCHEMBL21786889 | 0.92 | P2RX3 (0.47) | P2RX3P2RX1P2RX2POLBP2RX4 | |
| SCHEMBL21786819 | 0.92 | P2RY1 (0.45) | P2RX3P2RX1POLBP2RX4P2RY1 | |
| SCHEMBL24913567 | 0.91 | P2RX1 (0.45) | P2RX3P2RX1P2RX2POLBP2RX4 | |
| SCHEMBL21787123 | 0.90 | POLB (0.45) | POLBP2RY1P2RY2SRCSMN1; SMN2 | |
| SCHEMBL21786830 | 0.90 | CHAT (0.45) | P2RX3P2RX1P2RX2POLBP2RX4 | |
| SCHEMBL21786896 | 0.90 | CHAT (0.46) | P2RX3P2RX1P2RX2POLBP2RX4 | |
| SCHEMBL21787025 | 0.89 | P2RX3 (0.54) | P2RX3P2RX1P2RX2POLBP2RX4 | |
| SCHEMBL19662618 | 0.89 | P2RX3 (0.54) | P2RX3P2RX1P2RX2POLBP2RX4 | |
| SCHEMBL21787024 | 0.89 | P2RX3 (0.44) | P2RX3P2RX1P2RX2POLBP2RX4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230028321-A1 | NUCLEOTIDE DERIVATIVES AND METHODS OF USE THEREOF | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2023-01-26 | — | — | US | disclosed |
| US-20200069717-A1 | NUCLEOTIDE DERIVATIVES AND METHODS OF USE THEREOF | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2020-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200069717-A1 | NUCLEOTIDE DERIVATIVES AND METHODS OF USE THEREOF | POLRMT, NSUN2, RNGTT | P2RX3 1115/4885P2RX1 1554/4885P2RX2 1590/4885 |
| US-20230028321-A1 | NUCLEOTIDE DERIVATIVES AND METHODS OF USE THEREOF | POLRMT, NSUN2, NUDT1 | P2RX3 903/4885P2RX1 1240/4885P2RX2 1300/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.